Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Basel cocktail + rifampicin is a combination used in clinical pharmacology research to study drug-drug interactions and cytochrome P450 (CYP) enzyme activity. The Basel cocktail is a phenotyping tool containing six probe drugs (caffeine, efavirenz, flurbiprofen, metoprolol, midazolam, and omeprazole), each targeting specific CYP enzymes. Rifampicin is a potent CYP enzyme inducer that significantly affects drug metabolism. When administered together, researchers can assess how rifampicin's enzyme-inducing properties affect the metabolism of the cocktail components, providing valuable information about drug interactions and metabolic pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Basel cocktail + rifampicin.